Factors  ||| S:0 E:8 ||| NNS
related  ||| S:8 E:16 ||| VBN
to  ||| S:16 E:19 ||| TO
prognosis  ||| S:19 E:29 ||| VB
of  ||| S:29 E:32 ||| IN
refractory  ||| S:32 E:43 ||| JJ
glaucoma  ||| S:43 E:52 ||| NN
with  ||| S:52 E:57 ||| IN
diode  ||| S:57 E:63 ||| JJ
laser  ||| S:63 E:69 ||| NN
transscleral  ||| S:69 E:82 ||| VBZ
cyclophotocoagulation  ||| S:82 E:104 ||| JJ
treatment  ||| S:104 E:114 ||| NN
To  ||| S:114 E:117 ||| TO
evaluate  ||| S:117 E:126 ||| VB
the  ||| S:126 E:130 ||| DT
predictive  ||| S:130 E:141 ||| JJ
factors  ||| S:141 E:149 ||| NNS
of  ||| S:149 E:152 ||| IN
refractory  ||| S:152 E:163 ||| JJ
glaucoma  ||| S:163 E:172 ||| NNS
treated  ||| S:172 E:180 ||| VBN
with  ||| S:180 E:185 ||| IN
diode  ||| S:185 E:191 ||| FW
laser  ||| S:191 E:197 ||| FW
transscleral  ||| S:197 E:210 ||| FW
cyclophotocoagulation  ||| S:210 E:232 ||| FW
( ||| S:232 E:233 ||| -LRB-
TSCP ||| S:233 E:237 ||| NNP
)  ||| S:237 E:239 ||| -RRB-
in  ||| S:239 E:242 ||| IN
a  ||| S:242 E:244 ||| DT
midterm  ||| S:244 E:252 ||| JJ
observation ||| S:252 E:263 ||| NN
.  ||| S:263 E:265 ||| .
Fifty-four  ||| S:265 E:276 ||| JJ
consecutive  ||| S:276 E:288 ||| JJ
patients  ||| S:288 E:297 ||| NNS
( ||| S:297 E:298 ||| -LRB-
54  ||| S:298 E:301 ||| CD
eyes ||| S:301 E:305 ||| NNS
)  ||| S:305 E:307 ||| -RRB-
with  ||| S:307 E:312 ||| IN
refractory  ||| S:312 E:323 ||| JJ
glaucoma  ||| S:323 E:332 ||| NN
were  ||| S:332 E:337 ||| VBD
enrolled  ||| S:337 E:346 ||| JJ
and  ||| S:346 E:350 ||| CC
underwent  ||| S:350 E:360 ||| VBD
TSCP  ||| S:360 E:365 ||| NNP
( ||| S:365 E:366 ||| -LRB-
power  ||| S:366 E:372 ||| NN
of  ||| S:372 E:375 ||| IN
1.5-2.0  ||| S:375 E:383 ||| NNP
W ||| S:383 E:384 ||| NNP
,  ||| S:384 E:386 ||| ,
exposure  ||| S:386 E:395 ||| NN
time  ||| S:395 E:400 ||| NN
of  ||| S:400 E:403 ||| IN
2  ||| S:403 E:405 ||| CD
seconds  ||| S:405 E:413 ||| NNS
and  ||| S:413 E:417 ||| CC
20-50  ||| S:417 E:423 ||| CD
applications ||| S:423 E:435 ||| NNS
) ||| S:435 E:436 ||| -RRB-
.  ||| S:436 E:438 ||| .
Patients  ||| S:438 E:447 ||| NNS
were  ||| S:447 E:452 ||| VBD
regularly  ||| S:452 E:462 ||| RB
followed  ||| S:462 E:471 ||| VBN
up  ||| S:471 E:474 ||| RP
for  ||| S:474 E:478 ||| IN
12  ||| S:478 E:481 ||| CD
months ||| S:481 E:487 ||| NNS
.  ||| S:487 E:489 ||| .
Intraocular  ||| S:489 E:501 ||| JJ
pressure  ||| S:501 E:510 ||| NN
( ||| S:510 E:511 ||| -LRB-
IOP ||| S:511 E:514 ||| NNP
)  ||| S:514 E:516 ||| -RRB-
was  ||| S:516 E:520 ||| VBD
measured  ||| S:520 E:529 ||| VBN
before  ||| S:529 E:536 ||| IN
TSCP  ||| S:536 E:541 ||| NNP
treatment  ||| S:541 E:551 ||| NN
and  ||| S:551 E:555 ||| CC
at  ||| S:555 E:558 ||| IN
each  ||| S:558 E:563 ||| DT
follow-up  ||| S:563 E:573 ||| JJ
visit ||| S:573 E:578 ||| NN
.  ||| S:578 E:580 ||| .
Patients  ||| S:580 E:589 ||| NNS
were  ||| S:589 E:594 ||| VBD
divided  ||| S:594 E:602 ||| VBN
into  ||| S:602 E:607 ||| IN
the  ||| S:607 E:611 ||| DT
sensitive  ||| S:611 E:621 ||| JJ
and  ||| S:621 E:625 ||| CC
insensitive  ||| S:625 E:637 ||| JJ
groups  ||| S:637 E:644 ||| NNS
according  ||| S:644 E:654 ||| VBG
to  ||| S:654 E:657 ||| TO
the  ||| S:657 E:661 ||| DT
effect  ||| S:661 E:668 ||| NN
of  ||| S:668 E:671 ||| IN
a  ||| S:671 E:673 ||| DT
single  ||| S:673 E:680 ||| JJ
treatment  ||| S:680 E:690 ||| NN
of  ||| S:690 E:693 ||| IN
TSCP  ||| S:693 E:698 ||| NNP
on  ||| S:698 E:701 ||| IN
IOP ||| S:701 E:704 ||| NNP
.  ||| S:704 E:706 ||| .
The  ||| S:706 E:710 ||| DT
success  ||| S:710 E:718 ||| NN
rate  ||| S:718 E:723 ||| NN
was  ||| S:723 E:727 ||| VBD
defined  ||| S:727 E:735 ||| VBN
as  ||| S:735 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
percentage  ||| S:742 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
eyes  ||| S:756 E:761 ||| NNS
achieving  ||| S:761 E:771 ||| VBG
an  ||| S:771 E:774 ||| DT
IOP  ||| S:774 E:778 ||| NNP
between  ||| S:778 E:786 ||| IN
5  ||| S:786 E:788 ||| CD
and  ||| S:788 E:792 ||| CC
21  ||| S:792 E:795 ||| CD
mm  ||| S:795 E:798 ||| CD
Hg  ||| S:798 E:801 ||| NNS
following  ||| S:801 E:811 ||| VBG
TSCP  ||| S:811 E:816 ||| NNP
therapy  ||| S:816 E:824 ||| NN
at  ||| S:824 E:827 ||| IN
their  ||| S:827 E:833 ||| PRP$
final  ||| S:833 E:839 ||| JJ
follow  ||| S:839 E:846 ||| NN
up  ||| S:846 E:849 ||| IN
visit ||| S:849 E:854 ||| NN
.  ||| S:854 E:856 ||| .
Difference  ||| S:856 E:867 ||| NN
of  ||| S:867 E:870 ||| IN
age  ||| S:870 E:874 ||| NN
between  ||| S:874 E:882 ||| IN
the  ||| S:882 E:886 ||| DT
sensitive  ||| S:886 E:896 ||| JJ
and  ||| S:896 E:900 ||| CC
insensitive  ||| S:900 E:912 ||| JJ
groups  ||| S:912 E:919 ||| NNS
was  ||| S:919 E:923 ||| VBD
evaluated  ||| S:923 E:933 ||| VBN
with  ||| S:933 E:938 ||| IN
independent-samples  ||| S:938 E:958 ||| JJ
T  ||| S:958 E:960 ||| NN
test  ||| S:960 E:965 ||| NN
and  ||| S:965 E:969 ||| CC
that  ||| S:969 E:974 ||| IN
of  ||| S:974 E:977 ||| IN
gender  ||| S:977 E:984 ||| JJ
distribution  ||| S:984 E:997 ||| NN
of  ||| S:997 E:1000 ||| IN
two  ||| S:1000 E:1004 ||| CD
groups  ||| S:1004 E:1011 ||| NNS
was  ||| S:1011 E:1015 ||| VBD
evaluated  ||| S:1015 E:1025 ||| VBN
with  ||| S:1025 E:1030 ||| IN
Fisher ||| S:1030 E:1036 ||| NNP
's  ||| S:1036 E:1039 ||| POS
exact  ||| S:1039 E:1045 ||| JJ
test ||| S:1045 E:1049 ||| NN
.  ||| S:1049 E:1051 ||| .
The  ||| S:1051 E:1055 ||| DT
success  ||| S:1055 E:1063 ||| NN
rate  ||| S:1063 E:1068 ||| NN
of  ||| S:1068 E:1071 ||| IN
different  ||| S:1071 E:1081 ||| JJ
types  ||| S:1081 E:1087 ||| NNS
of  ||| S:1087 E:1090 ||| IN
glaucoma  ||| S:1090 E:1099 ||| VBG
to  ||| S:1099 E:1102 ||| TO
TSCP  ||| S:1102 E:1107 ||| NNP
was  ||| S:1107 E:1111 ||| VBD
calculated ||| S:1111 E:1121 ||| VBN
.  ||| S:1121 E:1123 ||| .
A  ||| S:1123 E:1125 ||| DT
total  ||| S:1125 E:1131 ||| NN
of  ||| S:1131 E:1134 ||| IN
32  ||| S:1134 E:1137 ||| CD
patients  ||| S:1137 E:1146 ||| NNS
were  ||| S:1146 E:1151 ||| VBD
sensitive  ||| S:1151 E:1161 ||| JJ
to  ||| S:1161 E:1164 ||| TO
TSCP  ||| S:1164 E:1169 ||| NNP
( ||| S:1169 E:1170 ||| -LRB-
sensitive  ||| S:1170 E:1180 ||| JJ
group ||| S:1180 E:1185 ||| NN
)  ||| S:1185 E:1187 ||| -RRB-
and  ||| S:1187 E:1191 ||| CC
22  ||| S:1191 E:1194 ||| CD
patients  ||| S:1194 E:1203 ||| NNS
were  ||| S:1203 E:1208 ||| VBD
insensitive  ||| S:1208 E:1220 ||| VBN
to  ||| S:1220 E:1223 ||| TO
TSCP  ||| S:1223 E:1228 ||| NNP
( ||| S:1228 E:1229 ||| -LRB-
insensitive  ||| S:1229 E:1241 ||| JJ
group ||| S:1241 E:1246 ||| NN
) ||| S:1246 E:1247 ||| -RRB-
.  ||| S:1247 E:1249 ||| .
The  ||| S:1249 E:1253 ||| DT
success  ||| S:1253 E:1261 ||| NN
rates  ||| S:1261 E:1267 ||| NNS
of  ||| S:1267 E:1270 ||| IN
female  ||| S:1270 E:1277 ||| JJ
( ||| S:1277 E:1278 ||| -LRB-
77.8 ||| S:1278 E:1282 ||| NNP
% ||| S:1282 E:1283 ||| NN
,  ||| S:1283 E:1285 ||| ,
14 ||| S:1285 E:1287 ||| CD
/ ||| S:1287 E:1288 ||| CD
18 ||| S:1288 E:1290 ||| CD
)  ||| S:1290 E:1292 ||| -RRB-
and  ||| S:1292 E:1296 ||| CC
cases  ||| S:1296 E:1302 ||| NNS
being  ||| S:1302 E:1308 ||| VBG
over  ||| S:1308 E:1313 ||| IN
50  ||| S:1313 E:1316 ||| CD
years  ||| S:1316 E:1322 ||| NNS
( ||| S:1322 E:1323 ||| -LRB-
71.4 ||| S:1323 E:1327 ||| NNP
% ||| S:1327 E:1328 ||| NN
,  ||| S:1328 E:1330 ||| ,
20 ||| S:1330 E:1332 ||| CD
/ ||| S:1332 E:1333 ||| CD
28 ||| S:1333 E:1335 ||| CD
)  ||| S:1335 E:1337 ||| -RRB-
were  ||| S:1337 E:1342 ||| VBD
higher  ||| S:1342 E:1349 ||| JJR
than  ||| S:1349 E:1354 ||| IN
those  ||| S:1354 E:1360 ||| DT
of  ||| S:1360 E:1363 ||| IN
male  ||| S:1363 E:1368 ||| JJ
( ||| S:1368 E:1369 ||| -LRB-
50.0 ||| S:1369 E:1373 ||| NNP
% ||| S:1373 E:1374 ||| NN
,  ||| S:1374 E:1376 ||| ,
18 ||| S:1376 E:1378 ||| CD
/ ||| S:1378 E:1379 ||| CD
36 ||| S:1379 E:1381 ||| CD
)  ||| S:1381 E:1383 ||| -RRB-
and  ||| S:1383 E:1387 ||| CC
ones  ||| S:1387 E:1392 ||| NNS
being  ||| S:1392 E:1398 ||| VBG
under  ||| S:1398 E:1404 ||| IN
50  ||| S:1404 E:1407 ||| CD
years  ||| S:1407 E:1413 ||| NNS
( ||| S:1413 E:1414 ||| -LRB-
46.2 ||| S:1414 E:1418 ||| CD
% ||| S:1418 E:1419 ||| NN
,  ||| S:1419 E:1421 ||| ,
12 ||| S:1421 E:1423 ||| CD
/ ||| S:1423 E:1424 ||| CD
26 ||| S:1424 E:1426 ||| CD
)  ||| S:1426 E:1428 ||| -RRB-
( ||| S:1428 E:1429 ||| -LRB-
all  ||| S:1429 E:1433 ||| DT
P ||| S:1433 E:1434 ||| NN
> ||| S:1434 E:1435 ||| CD
0.05 ||| S:1435 E:1439 ||| CD
) ||| S:1439 E:1440 ||| -RRB-
.  ||| S:1440 E:1442 ||| .
The  ||| S:1442 E:1446 ||| DT
age  ||| S:1446 E:1450 ||| NN
of  ||| S:1450 E:1453 ||| IN
the  ||| S:1453 E:1457 ||| DT
sensitive  ||| S:1457 E:1467 ||| JJ
and  ||| S:1467 E:1471 ||| CC
insensitive  ||| S:1471 E:1483 ||| JJ
groups  ||| S:1483 E:1490 ||| NNS
was  ||| S:1490 E:1494 ||| VBD
56.0+ ||| S:1494 E:1499 ||| CD
/ ||| S:1499 E:1500 ||| CD
-15.5  ||| S:1500 E:1506 ||| CD
and  ||| S:1506 E:1510 ||| CC
46.4+ ||| S:1510 E:1515 ||| CD
/ ||| S:1515 E:1516 ||| CD
-15.4  ||| S:1516 E:1522 ||| CD
years ||| S:1522 E:1527 ||| NNS
,  ||| S:1527 E:1529 ||| ,
respectively  ||| S:1529 E:1542 ||| RB
( ||| S:1542 E:1543 ||| -LRB-
P=0.029 ||| S:1543 E:1550 ||| NNP
) ||| S:1550 E:1551 ||| -RRB-
.  ||| S:1551 E:1553 ||| .
The  ||| S:1553 E:1557 ||| DT
age  ||| S:1557 E:1561 ||| NN
( ||| S:1561 E:1562 ||| -LRB-
P=0.029 ||| S:1562 E:1569 ||| NNP
)  ||| S:1569 E:1571 ||| -RRB-
and  ||| S:1571 E:1575 ||| CC
gender  ||| S:1575 E:1582 ||| JJ
distribution  ||| S:1582 E:1595 ||| NN
( ||| S:1595 E:1596 ||| -LRB-
P=0.046 ||| S:1596 E:1603 ||| NNP
)  ||| S:1603 E:1605 ||| -RRB-
of  ||| S:1605 E:1608 ||| IN
the  ||| S:1608 E:1612 ||| DT
two  ||| S:1612 E:1616 ||| CD
groups  ||| S:1616 E:1623 ||| NNS
had  ||| S:1623 E:1627 ||| VBD
significant  ||| S:1627 E:1639 ||| JJ
difference ||| S:1639 E:1649 ||| NN
.  ||| S:1649 E:1651 ||| .
The  ||| S:1651 E:1655 ||| DT
success  ||| S:1655 E:1663 ||| NN
rate  ||| S:1663 E:1668 ||| NN
of  ||| S:1668 E:1671 ||| IN
neovascular  ||| S:1671 E:1683 ||| JJ
glaucoma ||| S:1683 E:1691 ||| NN
,  ||| S:1691 E:1693 ||| ,
primary  ||| S:1693 E:1701 ||| JJ
angle-closure  ||| S:1701 E:1715 ||| JJ
glaucoma ||| S:1715 E:1723 ||| NN
,  ||| S:1723 E:1725 ||| ,
primary  ||| S:1725 E:1733 ||| JJ
open  ||| S:1733 E:1738 ||| JJ
angle  ||| S:1738 E:1744 ||| NN
glaucoma ||| S:1744 E:1752 ||| NN
,  ||| S:1752 E:1754 ||| ,
traumatic  ||| S:1754 E:1764 ||| JJ
glaucoma ||| S:1764 E:1772 ||| NN
,  ||| S:1772 E:1774 ||| ,
uveitic  ||| S:1774 E:1782 ||| JJ
glaucoma ||| S:1782 E:1790 ||| NN
,  ||| S:1790 E:1792 ||| ,
and  ||| S:1792 E:1796 ||| CC
secondary  ||| S:1796 E:1806 ||| JJ
glaucoma  ||| S:1806 E:1815 ||| NN
after  ||| S:1815 E:1821 ||| IN
silicone  ||| S:1821 E:1830 ||| JJ
oil  ||| S:1830 E:1834 ||| NN
injection  ||| S:1834 E:1844 ||| NN
to  ||| S:1844 E:1847 ||| TO
TSCP  ||| S:1847 E:1852 ||| NNP
was  ||| S:1852 E:1856 ||| VBD
57.1 ||| S:1856 E:1860 ||| CD
% ||| S:1860 E:1861 ||| NN
,  ||| S:1861 E:1863 ||| ,
100.0 ||| S:1863 E:1868 ||| CD
% ||| S:1868 E:1869 ||| NN
,  ||| S:1869 E:1871 ||| ,
50.0 ||| S:1871 E:1875 ||| CD
% ||| S:1875 E:1876 ||| NN
,  ||| S:1876 E:1878 ||| ,
20.0 ||| S:1878 E:1882 ||| CD
% ||| S:1882 E:1883 ||| NN
,  ||| S:1883 E:1885 ||| ,
81.8 ||| S:1885 E:1889 ||| CD
% ||| S:1889 E:1890 ||| NN
,  ||| S:1890 E:1892 ||| ,
and  ||| S:1892 E:1896 ||| CC
0 ||| S:1896 E:1897 ||| CD
% ||| S:1897 E:1898 ||| NN
,  ||| S:1898 E:1900 ||| ,
respectively ||| S:1900 E:1912 ||| RB
.  ||| S:1912 E:1914 ||| .
Age ||| S:1914 E:1917 ||| NN
,  ||| S:1917 E:1919 ||| ,
gender ||| S:1919 E:1925 ||| NN
,  ||| S:1925 E:1927 ||| ,
and  ||| S:1927 E:1931 ||| CC
type  ||| S:1931 E:1936 ||| NN
of  ||| S:1936 E:1939 ||| IN
glaucoma  ||| S:1939 E:1948 ||| NNS
appear  ||| S:1948 E:1955 ||| VBP
to  ||| S:1955 E:1958 ||| TO
be  ||| S:1958 E:1961 ||| VB
associated  ||| S:1961 E:1972 ||| VBN
with  ||| S:1972 E:1977 ||| IN
effect  ||| S:1977 E:1984 ||| NN
of  ||| S:1984 E:1987 ||| IN
TSCP  ||| S:1987 E:1992 ||| NNP
on  ||| S:1992 E:1995 ||| IN
IOP  ||| S:1995 E:1999 ||| NNP
control ||| S:1999 E:2006 ||| NN
.  ||| S:2006 E:2008 ||| .
